505(b)(1)

LXP107

Addressing the frequent FLT3 mutations in Acute Myeloid Leukemia (AML), LXP107 features as a selective small-molecule inhibitor designed to block aberrant signaling pathways. The R&D advantage lies in its ability to precisely suppress leukemic cell growth, directly addressing the poor prognosis and rapid disease progression associated with these genetic drivers. By enhancing therapeutic selectivity and targeting key oncogenic pathways, we offers a high-precision strategy for hematologic malignancies treatments.

Therapeutic Area:

FLT3-mutated Acute Myeloid Leukemia (AML)

Development Value

For acute myeloid leukemia, this selective inhibitor targets abnormal genetic signaling to suppress leukemic cell growth, providing a more precise and safer treatment strategy.

Latest Progress

Development Stage

Preclinical

IND

Phase I

Phase II

Phase III

NDA

Preclinical

Patents

Patents have been granted in Taiwan, Japan, China,  Australia and the United States, with applications filed in other countries still in progress.

  • Taiwan
  • Japan
  • China
  • Australia
  • United States